Asthma and obesity: endotoxin another insult to add to injury?

Abstract

Low-grade inflammation is often an underlying cause of several chronic diseases such as asthma, obesity, cardiovascular disease, and type 2 diabetes mellitus (T2DM). Defining the mediators of such chronic low-grade inflammation often appears dependent on which disease is being investigated. However, downstream systemic inflammatory cytokine responses in these diseases often overlap, noting there is no doubt more than one factor at play to heighten the inflammatory response. Furthermore, it is increasingly believed that diet and an altered gut microbiota may play an important role in the pathology of such diverse diseases. More specifically, the inflammatory mediator endotoxin, which is a complex lipopolysaccharide (LPS) derived from the outer membrane cell wall of Gram-negative bacteria and is abundant within the gut microbiota, and may play a direct role alongside inhaled allergens in eliciting an inflammatory response in asthma. Endotoxin has immunogenic effects and is sufficiently microscopic to traverse the gut mucosa and enter the systemic circulation to act as a mediator of chronic low-grade inflammation in disease. Whilst the role of endotoxin has been considered in conditions of obesity, cardiovascular disease and T2DM, endotoxin as an inflammatory trigger in asthma is less well understood. This review has sought to examine the current evidence for the role of endotoxin in asthma, and whether the gut microbiota could be a dietary target to improve disease management. This may expand our understanding of endotoxin as a mediator of further low-grade inflammatory diseases, and how endotoxin may represent yet another insult to add to injury.

Helicobacter pylori and Alzheimer’s Disease-Related Metabolic Dysfunction: Activation of TLR4/Myd88 Inflammation Pathway from p53 Perspective and a Case Study of Low-Dose Radiation Intervention

“…51 Occludin and ZO-1 help sustain the gut barrier integrity and protect normal gut permeability. Recently, it was suggested that low-grade inflammation is often an underlying case of metabolic dysfunction including obesity, type 2 diabetes mellitus, and cardiovascular disease, 52 and modulating the gut microbiota serves as a therapeutic intervention for diabets. 53 Therefore, targeting H. pylori may be a potential for early intervention for prevention of ADrelated MD.…”

Network pharmacology-based prediction of active compounds in the Wenyang Jiedu Huayu formula acting on acute-on-chronic liver failure with experimental support in vitro and in vivo

“…Numerous factors, such as endotoxin and pro-inflammatory cytokines, have been linked to the disease’s pathogenesis ( Zhou M. et al, 2019 ; Kessoku et al, 2021 ; Lad et al, 2021 ). Host immunity, resulting in the release of pro-inflammatory cytokines and activation of the excessive immune cascade, is accompanied by significant liver damage in the early stages of ACLF ( Liu, 2009 ).…”

Impact of Comorbidity of Bronchial Asthma and Type 2 Diabetes Mellitus on the Expression and Functional Activity of TLR2 and TLR4 Receptors

“…The Th2 phenotype is generally harder to control, and it reacts to the treatment with more poor results. A non-Th2 phenotype of severe asthma, which occurs because of a neutrophil immune response, is also related to the resistance to corticosteroids, which complicates selection of a treatment scheme [ 27 ].…”